Cantor Fitzgerald Brokers Reduce Earnings Estimates for PTCT

Key Points

• Cantor Fitzgerald has revised its FY2026 earnings per share estimate for PTC Therapeutics down to ($6.71), highlighting a pessimistic outlook for the biopharmaceutical company.
• Despite the downgrade, PTC Therapeutics still holds an "Overweight" rating from Cantor Fitzgerald with a price objective of $120.00. Other analysts have varying ratings and target prices, with a consensus rating of "Moderate Buy."
• PTC's recent quarterly results exceeded expectations, with reported earnings of ($0.83) EPS, which was better than the forecasted ($1.07) EPS, indicative of resilience despite a year-over-year revenue decline.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Equities researchers at Cantor Fitzgerald lowered their FY2026 earnings per share (EPS) estimates for PTC Therapeutics in a research report issued on Wednesday, August 20th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($6.71) for the year, down from their prior forecast of ($6.57). Cantor Fitzgerald currently has a "Overweight" rating and a $120.00 target price on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. PTC Therapeutics had a negative return on equity of 106.31% and a net margin of 35.65%.The business had revenue of $178.88 million during the quarter, compared to analysts' expectations of $173.01 million. During the same quarter last year, the business posted ($1.29) earnings per share. The business's revenue for the quarter was down 4.2% on a year-over-year basis. PTC Therapeutics has set its FY 2025 guidance at EPS.

A number of other analysts have also commented on the company. Morgan Stanley decreased their price objective on PTC Therapeutics from $76.00 to $71.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 20th. UBS Group lifted their price target on PTC Therapeutics from $71.00 to $80.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Citigroup lifted their price target on PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a report on Monday, July 28th. Wells Fargo & Company lowered their price target on PTC Therapeutics from $79.00 to $73.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $63.00 price objective (up from $60.00) on shares of PTC Therapeutics in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $69.15.

PTC Therapeutics Stock Up 1.3%

Shares of PTCT traded up $0.62 during trading hours on Friday, reaching $50.08. 241,924 shares of the company traded hands, compared to its average volume of 1,079,379. The stock has a market capitalization of $3.98 billion, a PE ratio of 7.19 and a beta of 0.54. PTC Therapeutics has a fifty-two week low of $30.41 and a fifty-two week high of $58.38. The stock has a fifty day simple moving average of $48.78 and a 200 day simple moving average of $49.03.

Insider Buying and Selling at PTC Therapeutics

In other news, CEO Matthew B. Klein sold 10,739 shares of the stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $51.74, for a total value of $555,635.86. Following the completion of the transaction, the chief executive officer owned 337,767 shares of the company's stock, valued at approximately $17,476,064.58. This represents a 3.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Pierre Gravier sold 2,516 shares of the stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total value of $124,441.36. Following the completion of the transaction, the chief financial officer directly owned 71,920 shares of the company's stock, valued at approximately $3,557,163.20. The trade was a 3.38% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

Institutional investors have recently modified their holdings of the company. Sterling Capital Management LLC lifted its holdings in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 522 shares during the period. Quantbot Technologies LP lifted its holdings in shares of PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 551 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 320 shares during the period. GAMMA Investing LLC lifted its holdings in shares of PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 441 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of PTC Therapeutics by 247.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,143 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 814 shares during the period.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.